Mazdutide is a dual-receptor medicine approved in China
Mazdutide is a peptide agonist of the GLP-1 and glucagon receptors. It received its first marketing approval in China in June 2025 for chronic weight management in specified adults with obesity or overweight and weight-related comorbidity.[1] Approval is jurisdiction-, product-, and indication-specific; it does not make an online research vial equivalent to the authorized Chinese product.
Phase 3 evidence supports the approved population
In a phase 3 double-blind trial in China, adults received mazdutide or placebo for 48 weeks. At week 48, estimated mean weight change was −11.0% with 4 mg, −14.0% with 6 mg, and +0.3% with placebo.[2] Gastrointestinal adverse events were common. These results support a defined clinical product and population, not unmonitored use or extrapolation to different vial formulations.
Safety and generalizability
The trial evidence comes predominantly from Chinese adults and defined titration and monitoring protocols. Long-term outcomes, rare harms, pregnancy use, interactions, and performance in broader populations require product labeling and continuing pharmacovigilance. Class-related concerns from other GLP-1 medicines are relevant clinical background but should not be presented as measured mazdutide incidence unless the mazdutide label or trials report them.
U.S. status remains unapproved
Mazdutide does not have FDA marketing approval in the United States. FDA's 2026 warning letter treated an online mazdutide product promoted for human use as an unapproved new drug.[3] Teloryx does not transfer the Chinese product's labeling or trial schedule to research vials and does not publish a self-use titration or reconstitution recipe.